ReviewDementia & neuropsychologia2025
Efficacy of medications in controlling cognitive dysfunction in Alzheimer's : a systematic review.
Review in Dementia & neuropsychologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia is one of the biggest global health crises of the 21st century. It is known that Alzheimer's disease (AD) is the most common cause of dementia. Therefore, developing drugs with the potential to alter disease progression has been a priority. Objective: This study aims to review the efficacy and safety of drugs for AD. Methods: Based on the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) document, a systematic review was carried out in different databases. The Alzheimer's Disease Assessment Scale (ADAS-Cog) was used as the primary outcome. The risk of bias was checked using the Risk of Bias in Randomized Trials (RoB 2). Results: A systematic review resulted in 64 articles which were included in the analysis. The main medications discussed were: donepezil, which demonstrated a significant improvement in cognitive function, with good tolerability, although it has limitations in patients with swallowing difficulties. Transdermal patches showed similar effectiveness and were recently approved. Galantamine showed benefits on cognitive function, with good tolerability. Rivastigmine was effective and presented in transdermal form with similar efficacy to capsules, but had mainly gastrointestinal adverse effects. Pioglitazone showed no significant results initially, but some studies suggest benefits in patients with AD associated with type II diabetes mellitus. Conclusion: The studies reviewed indicate that, although some current medications such as donepezil, galantamine, and rivastigmine have modest, well-established benefits in clinical practice, many new agents have not yet demonstrated significant efficacy in modifying AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.